Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. (Q36841028)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

Iñaki Gutierrez-Ibarluzea

2 March 2020

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Laura McCullagh

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Lars L. Gustafsson

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1

Rickard E Malmström

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

2

Brian B Godman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

5

Marion Bennie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

8

Anna Bucsics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

10

Alessandra Ferrario

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

12

Jurij Fürst

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

16

Alan Haycox

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

17

Krystyna Hviding

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

18

Harald Herholz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

20

Saira Jan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

22

Roberta Joppi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

23

Marija Kalaba

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

24

Christina Kvalheim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

25

Ott Laius

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

29

Kamila Malinowska

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

31

Ken Paterson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Vanda Markovic-Pekovic

32

object named as

Vanda Markovic-Pekovic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

34

Jutta Piessnegger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

35

Gisbert Selke

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

36

Catherine Sermet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

37

Steven Simoens

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

39

Dominik Tomek

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

40

Luka Vončina

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Vera Vlahovic-Palcevski

41

object named as

Vera Vlahovic-Palcevski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

42

Janet Wale

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

44

Magdalena Wladysiuk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

45

Menno van Woerkom

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

46

Corrine Zara

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

4

Christoph Baumgärtel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

13

Kristina Garuoliene

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Alexander E Finlayson

11

object named as

Alexander E Finlayson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Eduard Diogene

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Iain Bishop

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Anna Brzezinska

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Miguel Gomes

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Mikael Hoffmann

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Jan Jones

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Irene Langner

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Julie Lonsdale

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sven-Äke Lööv

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Andrew Martin

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Cankat Tulunay

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Michael Wilcock

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

14 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

Frontiers in Pharmacology

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?

2 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Dabigatran and postmarketing reports of bleeding

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Discounts and rebates granted to public payers for medicines in European countries

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

International variability in the reimbursement of cancer drugs by publically funded drug programs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Generic atorvastatin and health care costs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Policies to enhance prescribing efficiency in europe: findings and future implications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Controversies of anticoagulation reversal in life-threatening bleeds

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

What principles should govern the use of managed entry agreements?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Pharmacotherapies for obesity: past, current, and future therapies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Forecasting drug utilization and expenditure in a metropolitan health region

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Dabigatran versus warfarin in patients with atrial fibrillation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

The psychiatric side-effects of rimonabant

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Characteristics of and trends in the late-stage biopharmaceutical pipeline

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Balancing Big Pharma's books

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Outcome parameters for trials in atrial fibrillation: executive summary

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Delaying generic competition--corporate payoffs and the future of Plavix

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Lifetime risk for development of atrial fibrillation: the Framingham Heart Study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Psychotherapy for patients with complex disorders and chronic symptoms. The need for a new research paradigm.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

The safety of newly approved medicines: do recent market removals mean there is a problem?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Guillain-Barré syndrome following zimeldine treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

GSK backs campaign for disclosure of trial data

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Is there a cure for corporate crime in the drug industry?

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Concerns about storage and application of dabigatran and rivaroxaban

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Sale strategies of pharmaceutical companies in a "pharmerging" country: the problems will not improve if the gaps remain.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Personalized medicine. New cystic fibrosis drug offers hope, at a price.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

5 September 2018

2011 FDA drug approvals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Impact of restricted reimbursement on the use of statins in Finland: a register-based study

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

New oral antithrombotics: a need for laboratory monitoring. For.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

New drug in atrial fibrillation--how does it function in regular health care?

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

The ongoing regulation of generic drugs.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Search for pair production of a heavy up-type quark decaying to a W boson and a b quark in the lepton + jets channel with the ATLAS detector

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Delivering affordable cancer care in high-income countries

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

20 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Enhancing the rational use of new medicines across European health care systems

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3653065

Effectiveness versus efficacy: more than a debate over language

4 December 2018

1 reference

12 December 2020

Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association

1 reference

12 December 2020

Sociology of pharmaceuticals development and regulation: a realist empirical research programme

1 reference

12 December 2020

Risk sharing agreements: what lessons from Italy?

1 reference

12 December 2020

European countries with small populations can obtain low prices for drugs: Lithuania as a case history

1 reference

12 December 2020

Natalizumab for multiple sclerosis: a complicated treatment

1 reference

12 December 2020

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial

1 reference

12 December 2020

New drugs for thromboprophylaxis in atrial fibrillation

1 reference

12 December 2020

The danger of imperfect regulation: OxyContin use in the United States and Canada

1 reference

12 December 2020

Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland

1 reference

12 December 2020

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice

1 reference

12 December 2020

Bleeding Risk with Dabigatran in the Frail Elderly

1 reference

12 December 2020

Pharmaceutical companies' role in state vaccination policymaking: the case of human papillomavirus vaccination

1 reference

12 December 2020

Monitoring new oral anticoagulants, managing thrombosis, or both?

1 reference

12 December 2020

Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate

1 reference

12 December 2020

The pharmaceutical market for obesity therapies

1 reference

12 December 2020

Improving the managed entry of new medicines: sharing experiences across Europe

1 reference

12 December 2020

Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?

1 reference

12 December 2020

Identifiers

DOI

10.3389/FPHAR.2013.00039

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23717279%20AND%20SRC:MED&resulttype=core&format=json